Impact Analysis of Covid-19
The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Dementia is one of the most prevalent neurodegenerative diseases in which patients suffer from various behavioral changes, as a primary symptoms such as decline in memory or other thinking skills and can gets worse as condition progresses. It majorly affects people of aged 65 years and above. Currently, there is no curative therapy available for dementia disease. However, drugs for dementia therapy are in pipeline, which are expected to be launched in the near future, in turn propelling growth of the dementia drugs market.
Market Dynamics
Increasing aging population along with its associated complications is the major driving factor for growth of the dementia drugs market. For instance, according to Centers of Disease Control and Prevention (CDC), 2013, five million people were suffering from AD and the number is expected to rise up to 14 million by 2050, in the U.S. Moreover, according to World Health Organization (WHO), 2017, around 47 million people suffer from dementia and around 10 million new cases are reported annually. Increasing incidence of dementia coupled with growing demand for therapy is expected to favor growth of the dementia drugs market in the near future. According to Australian Institute of Health and Welfare (AIHW) estimates, the number of people with dementia is expected to reach to around 400,000 by 2020, and around 900,000 by 2050. Moreover, the National Health and Medical Research Council (NHMRC) is working in collaboration with the Australian Research Council (ARC) to prioritize and fund new dementia research projects and translate research to improve prevention, diagnosis, treatment, and care for dementia patients.
Key features of the study:
• This report provides in-depth analysis of the dementia drugs market, market size (US$ Mn) and cumulative annual growth rate (CAGR (%)) for the forecast period: 2018 - 2026, considering 2017 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by the leading players
• It profiles leading players in the global dementia drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
• Key players covered as a part of this study include Eisai, Inc., Janssen Pharmaceuticals, Inc., Biogen Pharmaceuticals, Forest Laboratories, Inc., Eli Lilly and Company, Novartis AG, Sanofi S.A., AstraZeneca GmbH, F. Hoffmann-La Roche, Merck & Co., Inc., Valeant Pharmaceutical International, Pfizer Inc., and Teva Pharmaceuticals Industries Ltd
• Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, market expansion, and marketing tactics
• The global dementia drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers for dementia drugs market, research and consulting firms, new entrants, and financial analysts
Detailed Segmentation:
• Global Dementia Drugs Market, By Drug Class:
o MAO Inhibitors
o Cholinesterase Inhibitors
o Glutamate Inhibitors
• Global Dementia Drugs Market, By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Others
• Global Dementia Drugs Market, By Region:
o North America
o By Country:
o U.S.
o Canada
o By Drug Class:
o MAO Inhibitors
o Cholinesterase Inhibitors
o Glutamate Inhibitors
o By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Others
o Europe
o By Country:
o U.K.
o Germany
o Italy
o Spain
o France
o Russia
o Rest of Europe
o By Drug Class:
o MAO Inhibitors
o Cholinesterase Inhibitors
o Glutamate Inhibitors
o By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Others
o Asia Pacific
o By Country:
o Australia
o India
o China
o Japan
o ASEAN
o South Korea
o Rest of Asia Pacific
o By Drug Class:
o MAO Inhibitors
o Cholinesterase Inhibitors
o Glutamate Inhibitors
o By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Others
o Latin America
o By Country:
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o By Drug Class:
o MAO Inhibitors
o Cholinesterase Inhibitors
o Glutamate Inhibitors
o By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Others
o Middle East
o By Country:
o GCC
o Israel
o Rest of Middle East
o By Drug Class:
o MAO Inhibitors
o Cholinesterase Inhibitors
o Glutamate Inhibitors
o By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Others
o Africa
o By Country:
o South Africa
o Central Africa
o North Africa
o By Drug Class:
o MAO Inhibitors
o Cholinesterase Inhibitors
o Glutamate Inhibitors
o By Distribution Channel:
o Hospital Pharmacies
o Retail Pharmacies
o Others
• Company Profiles
o Eisai, Inc.*
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Highlights
o Strategies
o Janssen Pharmaceuticals, Inc.
o Biogen Pharmaceuticals
o Forest Laboratories, Inc.
o Eli Lilly and Company
o Novartis AG
o Sanofi S.A.
o AstraZeneca GmbH
o Hoffmann-La Roche
o Merck & Co., Inc.
o Valeant Pharmaceutical International
o Pfizer Inc.
o Teva Pharmaceuticals Industries Ltd
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objective and Assumption
o Research Objectives
o Assumptions
o Abbreviations
2. Market Overview
o Report Description
o Market Definition and Scope
o Executive Summary
o Market Snippet, By Drug Class
o Market Snippet, By Distribution Channel
o Market Snippet, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
o Drivers
o Restraints
o Market Opportunities
o Impact Analysis
o Market Trends
o Key Developments
o Pipeline Analysis
o Epidemiology
o Historical Overview
o Overview of Sub-classes of Drugs
o Revenue Potential of Drugs
o PORTER'S Five Forces
o PEST Analysis
4. Global Dementia Drugs Market, By Drug Class, 2016-2026, (US$ Million)
o Introduction
o Market Share Analysis, 2017 and 2026 (%)
o Y-o-Y Growth Analysis, 2017-2026
o Segment Trends
o MAO Inhibitors
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Million)
o Cholinesterase Inhibitors
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Million)
o Glutamate Inhibitors
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Million)
5. Global Dementia Drugs Market, By Distribution Channel, 2016-2026, (US$ Million)
o Introduction
o Market Share Analysis, 2017 and 2026 (%)
o Y-o-Y Growth Analysis, 2017-2026
o Segment Trends
o Hospital Pharmacies
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Million)
o Retail Pharmacies
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Million)
o Others
o Introduction
o Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Million)
6. Global Dementia Drugs Market, By Regions, 2016-2026, (US$ Million)
o Introduction
o Market Share Analysis, By Region, 2017 and 2026 (%)
o Y-o-Y Growth Analysis, By Region, 2017-2026
o Regional Trends
o North America
o Market Size and Forecast, By Drug Class, 2016-2026, (US$ Million)
o Market Size and Forecast, By Distribution Channel, 2016-2026, (US$ Million)
o Market Size and Forecast, By Country, 2016-2026, (US$ Million)
• U.S.
• Canada
o Europe
o Market Size and Forecast, By Drug Class, 2016-2026, (US$ Million)
o Market Size and Forecast, By Distribution Channel, 2016-2026, (US$ Million)
o Market Size and Forecast, By Country, 2016-2026, (US$ Million)
• U.K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
o Asia Pacific
o Market Size and Forecast, By Drug Class, 2016-2026, (US$ Million)
o Market Size and Forecast, By Distribution Channel, 2016-2026, (US$ Million)
o Market Size and Forecast, By Country, 2016-2026, (US$ Million)
• China
• Japan
• India
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
o Latin America
o Market Size and Forecast, By Drug Class, 2016-2026, (US$ Million)
o Market Size and Forecast, By Distribution Channel, 2016-2026, (US$ Million)
o Market Size and Forecast, By Country, 2016-2026, (US$ Million)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
o Africa
o Market Size and Forecast, By Drug Class, 2016-2026, (US$ Million)
o Market Size and Forecast, By Distribution Channel, 2016-2026, (US$ Million)
o Market Size and Forecast, By Country, 2016-2026, (US$ Million)
• Northern Africa
• Central Africa
• South Africa
o Middle East
o Market Size and Forecast, By Drug Class, 2016-2026, (US$ Million)
o Market Size and Forecast, By Distribution Channel, 2016-2026, (US$ Million)
o Market Size and Forecast, By Country, 2016-2026, (US$ Million)
• GCC Countries
• Israel
• Rest of Middle East
7. Competitive Landscape
o Heat Map Analysis
o Company Profiles
o Eisai, Inc.
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Highlights
• Strategies
o Janssen Pharmaceuticals, Inc.
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Highlights
• Strategies
o Biogen Pharmaceuticals
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Highlights
• Strategies
o Forest Laboratories, Inc.
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Highlights
• Strategies
o Eli Lilly and Company
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Highlights
• Strategies
o Novartis AG
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Highlights
• Strategies
o Sanofi S.A.
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Highlights
• Strategies
o AstraZeneca GmbH
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Highlights
• Strategies
o F. Hoffmann-La Roche
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Highlights
• Strategies
o Merck & Co., Inc.
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Highlights
• Strategies
o Valeant Pharmaceutical International
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Highlights
• Strategies
o Pfizer Inc.
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Highlights
• Strategies
o Teva Pharmaceuticals Industries Ltd
• Company Overview
• Product Portfolio
• Financial Performance
• Recent Highlights
• Strategies
o Analyst Views
8. Section
o References
o Research Methodology
o About Us and Sales Contact
*Browse 25 market data tables and 44 figures on "Dementia Drugs Market" - Global forecast to 2026".
